• 

  CTAD: Leqembi’s Origin Story, 30 Years Ago in Arctic Sweden
• 

  8/11 of the Doctors Who Advised on Kisunla Approval Had Conflicts of Interest
• 

  After Cassava Fraud Indictment, Questioning the Ethics of Simufilam Trial
• 

  FDA-Approved Zunveyl for Alzheimer’s Symptoms On the Way in 2025
• 

  What’s the Deal With Blood Pressure, Cholesterol, and Alzheimer’s Risk?

• Are Alzheimer’s Blood Tests Living Up to the Hype?
• 

  Coffee & Alzheimer’s Disease: What’s the Verdict?
• 

  Flu Season: Here’s What Skipping the Flu Vaccine Does to Your Dementia Risk
• 

  Untreated Blood Pressure, Significantly Higher Alzheimer’s Risk
• 

  Dementia Biomarkers 101: What is Tau?

• Athira’s Alzheimer’s Drug Fails in Later-stage Clinical Trial
• 

  For Patients on Discontinued Aduhelm, What Now?

• Does Long COVID Lead to Alzheimer’s? A New Study Took an Unexpected Turn
• 

  Do You Have Alzheimer’s? New Diagnostic Criteria Might Change the Answer
• 

  UK Health Services Says Leqembi Is Too Costly, Too Risky to Cover

Previous101112Next